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Abstract 
 
In a multi-center, prospective, observational study over two influenza seasons, we sought to 
quantify and correlate the amount of virus recovered from the nares of infected subjects 
with that recovered from their immediate environment in community and hospital settings. 
We recorded the symptoms of adults and children with A(H1N1)pdm09 infection, took nasal 
swabs, and sampled touched surfaces and room air. Forty-two infected subjects were 
followed up. The mean duration of virus shedding was 6.2 days by PCR (Polymerase Chain 
Reaction) and 4.2 days by culture. Surface swabs were collected from 39 settings; 16 (41%) 
subject locations were contaminated with virus. Overall, 33 of the 671 (4.9%) surface swabs 
were PCR positive for influenza, of which two (0.3%) yielded viable virus. On illness Day 3, 
subjects yielding positive surface samples had significantly higher nasal viral loads 
(geometric mean ratio 25.7; 95% CI 1.75, 376.0, p=0.021) and a positive correlation (r= 
0.47, p= 0.006) was observed between subject nasal viral loads and viral loads recovered 
from the surfaces around them. Room air was sampled in the vicinity of 12 subjects, and 
PCR positive samples were obtained for five (42%) samples. Influenza virus shed by infected 
subjects did not detectably contaminate the vast majority of surfaces sampled. We question 
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the relative importance of the indirect contact transmission of influenza via surfaces, though 
our data support the existence of super-spreaders via this route. The air sampling results 
add to the accumulating evidence that supports the potential for droplet nuclei (aerosol) 
transmission of influenza. 
 
 
 
Introduction 
 
Little is definitively known about the modes of influenza transmission and their relative 
importance, and important health policy and infection control issues remain unresolved. The 
World Health Organization, the Centers for Disease Control and Prevention (CDC), the 
European Centre for Disease Prevention and Control and the U.S. Institute of Medicine have 
each prioritized improving the understanding of influenza transmission as a critical 
component for pandemic preparedness and response.1-3 
 
Influenza transmission begins with the production of virus containing particles by actions 
such as coughing and sneezing, which generate an ‘expiratory spray’ containing particles 
varying in size from <1 to 1000 µm. The majority are small and have a geometric mean 
diameter of 13.5 µm during coughing.4 Large droplets (typical size >20 µm) deposit on 
mucous surfaces of the upper respiratory tract (URT), such as the mouth and nose; they can 
be inhaled, but are too large to reach the lungs. Droplet nuclei (frequently called aerosols; 
typically ≤5 µm) are inhaled and can reach the lower respiratory tract (LRT).5 Contact 
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transmission involves the transfer of particles to the mucous membranes either directly, 
e.g., via kissing, or indirectly via hands or fomites. 
 
Laboratory studies have confirmed the ability of human influenza virus to survive in these 
environments,6-8 but few studies have attempted to investigate its presence, quantity and 
viability around infected patients. In previous research, viral shedding has mostly been 
determined by the measurement of the virus that is recoverable from the nasopharynx, i.e., 
via a deliberately performed invasive technique. Such ‘viral shedding’ studies in fact 
measure the virus shed from infected cells into the nasopharynx but do not actually 
measure the amount of virus deposited into the environment (on surfaces or in the air); 
therefore, they imply but do not define environmental contamination and the actual hazard 
posed to others. In this study, we describe viral shedding and its relationship to symptom 
duration, illness severity and the amount of virus recovered from the immediate 
environment. 
 
 
 
Methods 
 
We conducted a multi-center, prospective, observational cohort study over two influenza 
seasons, comprising the second and third waves of the 2009/10 pandemic in England 
[September 2009 - January 2010 (Year 1) & December 2010 – January 2011 (Year 2)]. An 
accredited UK Research Ethics Committee approved the study. 
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Participants 
Adults and children (<16 years) in hospitals and in the community were recruited from three 
sites in the UK. Written informed consent was obtained at enrolment for all participants. 
 
Screening and eligibility criteria 
We approached patients who had an influenza-like illness (ILI) defined as: fever (or recent 
history of fever) and any one of cough, sore throat, runny nose, fatigue or headache OR any 
two of cough, sore throat, runny nose, fatigue or headache. A rapid antigen test (Quidel 
QuickVue®) was used to assist with the early diagnosis of cases (but positivity was not an 
inclusion criterion). We excluded cases where illness had been present for >48 hours 
(community cases) or >96 hours (hospital cases). 
 
Study Procedures 
Where possible, subjects were followed up on a daily basis for a maximum of 12 days. A 
symptom diary was completed at each visit. 
 
A nasal swab, performed by a nurse or physician, was taken by rotating a swab round one 
anterior nare three times. Surface swabs were taken in hospital rooms and in the subjects’ 
own homes from pre-defined surfaces (Table A, supplementary data). The swabs were 
moistened with viral transport medium (VTM – Remel M4RT®) and then rubbed across an 
area of approximately 100 cm2 in three different directions while applying even pressure. 
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Nasal and surface swabs were placed into VTM and kept on ice for no longer than three 
hours before being frozen at -700C. 
 
Air particles were collected using a National Institute for Occupational Safety and Health 
two-stage cyclone bioaerosol sampler that separates particles into 3 size fractions [<1 µm 
(stage 1), 1-4 µm (stage 2) and >4 µm (stage 3)] and has been validated for use with 
influenza.9-10 Sampling was usually performed on only one day. The flow rate through each 
sampler was set to 3.5 L/min with a flow calibrator (Model 4143, TSI). Samplers were 
mounted on tripods at a height of 150 cm, placed approximately 2 m from the subject and 
run for 1-3 hours. After sampling, VTM was added to both stage 1 and 2 tubes and the filter 
paper from stage 3 was immersed in a 15-ml tube containing VTM. The samples were stored 
at –70°C. 
 
Further details are provided in Supplementary Table A. 
 
Virological Assessments 
Polymerase Chain Reaction (PCR):  A novel influenza A(H1N1) pentaplex assay was devised 
to detect the virus genome in the samples. The assay was designed to detect 
A(H1N1)pdm09, seasonal H1 and H3 influenza A, influenza B and an internal control 
bacteriophage MS2. It is highly sensitive and has a very wide dynamic range (10 logs) and 
can reliably detect as few as 3.85 genome equivalents per PCR reaction. The performance of 
the assay has been assessed on multiple occasions by Health Protection Agency/Public 
Health England external quality assessment panels. Viral load data for A(H1N1)pdm09 were 
generated using a PCR assay and a plasmid containing the hemagglutinin (HA) gene target 
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to create a standard curve, such that the concentration of the genome present in each 
sample could be estimated. 
 
Culture: An immunofluorescence (IF) assay was used to detect the influenza A/B 
nucleoprotein to demonstrate the presence of live replicating virus.11  
 
Further methodological detail is provided in the Supplementary Data section. 
 
The following sample processing rules were instituted to limit the analysis of likely negative 
samples: 
1. Nasal swabs from day 4 onwards were not tested if days 1-3 were all PCR negative. 
2. Culture was only performed on PCR positive samples. 
3. Environmental swabs were not processed if nasal swabs taken on the three previous 
days from a case were PCR negative 
 
Outcome Measures 
Virus shedding (nasal swab): 
A positive nasal swab was defined as a sample in which a cycle threshold (Ct) value of <35 
(2342 copies/ml) for ≥1 triplicate of a sample was obtained (a Ct value of 35 is a log up 
from the identified limit of detection of the assay). Unexplainable results and any single 
triplicates separated by >48 hours from other positive samples were disregarded. Viral loads 
represent the geometric mean (GM) value of the triplicate assay. A value of half of the lower 
limit of detection was imputed for undetectable values. The duration of virus shedding was 
defined as the time between symptom onset and the last day that a positive specimen was 
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obtained. Because subjects were seldom recruited on the day that symptoms began, an 
assumption was made that they were shedding virus from the first day of symptoms to the 
last positive specimen day. 
 
Subject symptoms: 
Daily symptom scores were categorized into the i) URT score; ii) the LRT score; iii) the 
systemic score; and iv) the total symptom score (sum of URT, LRT and systemic scores plus 
a score for diarrhea and/or vomiting). Individual symptoms were given a severity score of 0-
3. A similar index has previously been used to assess respiratory tract illnesses of viral 
etiology.12 
 
 
Environmental deposition (surfaces and air samples): 
A positive surface swab or air sample was defined as a sample in which a Ct value of <35 for 
≥1 triplicate of a sample was obtained. Post-hoc, a Ct value of <40 (122 copies/ml) for ≥1 
triplicate of a sample, if it was obtained from a subject with a positive nose swab taken on 
the same day (to help confirm plausibility), was defined as positive. Reducing the threshold 
of detection to limit false negative results was considered to be reasonable based on our 
own data that showed false positives to be unlikely; only 1 swab (Ct = 39.5) was excluded 
because of a negative nose swab on the same day. 
 
Statistical methods 
A descriptive analysis of the data is presented. Student’s t-tests were used to compare 
mean values; Pearson's correlation tests were used to determine associations between 
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continuous variables; and Odds Ratios (ORs) and 95% confidence intervals (CIs) represent 
associations between variables with binary categorical outcome measures. Chi-squared tests 
were used to test the significance of ORs. Differences in viral loads were measured using 
GMs and compared using GM ratios and paired t-tests. P values ≤0.05 were considered to 
be significant. All statistical analyses were conducted in Stata version 11 (Statacorp, Inc.). 
 
 
 
 
Results 
 
Demography, treatment and outcomes 
One-hundred-two subjects with ILI were studied, 49 (48%) of whom had a confirmed 
influenza infection; 44 (90%) had A(H1N1)pdm09 (age range 0 to 58); and 5 (10%) had 
influenza B (age range 5 to 66) (Figure 1). Two patients with A(H1N1)pdm09 were excluded 
from analysis because they were recruited outside of the specified timeframe. Therefore, 
data from 42 patients with confirmed A(H1N1)pdm09 cases are presented in this paper. The 
demography of these subjects is shown in Table 1.  
 
Symptoms 
The most frequently reported symptoms were cough (93%), sore throat (88%) and 
rhinorrhea (86%). During follow up, the symptom scores were highest on Day 3 of 
symptomatic illness and declined thereafter (Figure 2). 
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Virus Shedding 
PCR: 
The mean duration of shedding was 6.2 days from symptom onset (range 2-15 days, 
interquartile range 5-7). There was no significant difference between adults and children 
[mean difference = 0.29 (95% CI: -1.33, 1.90), p= 0.720] (Figure 3A). 
 
Viral loads varied widely, ranging from 2033 – 24,521,397 copies/ml, and declined over 
time. No significant differences were observed in the GM viral loads between adults vs. 
children and community vs. hospital cases on illness Days 3, 4 and 5 (Table B, 
supplementary data). 
Culture: 
Twenty-four of 39 cases (62%) were culture positive for A(H1N1)pdm09 (insufficient sample 
was available for culture in three cases). The mean duration of shedding by culture was 4.6 
days (range 3-10 days, interquartile range 4-5). Ten of 39 (26%) subjects shed live virus 
for at least five days from the onset of illness (Figure 3B). 
 
Environmental Deposition 
Surfaces: 
Multiple surface swabs were collected in 39 separate locations (houses and hospital rooms) 
inhabited by subjects, some of whom lived together; 16 premises (41%) were contaminated 
with virus. A mean of 16 swabs (range 6-42) were taken from each location, ≥2 positive 
samples were obtained from 8 of the 16 premises. In total, 671 collected swabs were tested 
and influenza A(H1N1)pdm09 was detected by PCR in 33 (4.9%). Seventeen surface 
samples (selected on the basis of PCR results with low Ct values) were examined for viable 
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virus, and two surfaces (a games console and a kettle handle) were positive, representing 
11.7% of the samples cultured and 0.3% of the total samples taken) (Table C, 
supplementary data). 
 
Air: 
Samples were collected from the immediate environment of 12 subjects (Season 1 = 5, 
Season 2 = 7). Subjects were targeted on the basis of a positive rapid test, early in the 
course of illness, convenience and special interest (HDU cases); six were in the hospital, 
nine were adults and eight were rapid antigen test positive. These samples were positive by 
PCR for five subjects (42%) (Table 2). Virus was detected in all of the particle size fractions 
collected; 7/26 (27%) of the collections for particles <1 µm were positive; 9/27 (33%) of 1-
4-µm particles were positive and 7/27 (26%) of >4-µm particles were positive. No 
significant associations were found with respect to the sampling distance or time and the 
finding of positive samples. Viral loads ranged between 238 and 24,231 copies/mL. No air 
samples were positively cultured.  
 
The relationship between symptoms, virus shedding and virus deposition 
Symptoms and viral load: 
Poor correlations were observed between the total symptom scores and log transformed 
nasal viral loads on illness Day 3 (day of maximum symptoms) (r= -0.063; p= 0.751) and 
Day 4 (r= -0.07; p= 0.69).  
 
Viral load and surface deposition of virus: 
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On illness Day 3, a significantly higher GM viral load was observed in those who had surface 
positive swabs compared to those who did not (GM ratio 25.7; 95% CI 1.75, 376.0, 
p=0.021) (Table 3). A positive correlation (r= 0.47, p= 0.006) was observed between the 
log transformed subject nasal viral loads and viral loads recovered from surfaces on illness 
Day 3 (r= 0.38, p= 0.03). 
 
Symptoms and surface deposition of virus: 
There were statistically significant findings for URT symptoms and similar but non-significant 
trends for LRT symptoms, which suggest that patients with higher symptom scores reflected 
in the likelihood of there being influenza positive surface swabs taken from the environment 
(Table 3). 
 
 
Symptoms, viral load and virus deposition in air: 
There were no differences in the GM viral loads on illness Day 4 or in the LRT and URT 
scores on illness Days 3 and 4 between those with positive and negative air samples (Table 
D, supplementary data). 
 
 
Discussion 
 
 
This is the first study to examine the relationship between influenza virus shedding from the 
nose with virus deposition in the air and on surfaces from the patient’s immediate 
environment, in both inpatient and home settings. As such, it offers important information 
for infection prevention and control practices.  
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Our findings on the duration of virus shedding are broadly in agreement with published 
findings concerning seasonal influenza and A(H1N1)pdm09,13-16 although we did not identify 
a significant correlation between symptoms and viral load where others have done so. Virus 
was detected on surfaces in the near environment of 38% of subjects. Overall, however, 
virus was infrequently isolated by PCR from surface swabs (4.9%), and on only two 
occasions was live (infectious) virus recovered. These data suggest that although 
environmental contamination occurs, it is not usually extensive or heavy.  
 
To our knowledge, there are no data concerning the infectious dose for indirect contact 
routes; however, we believe that the following data helps justify our conclusion. The ratio of 
the tissue culture infectious dose 50 (TCID50) to the number of virions (and therefore to the 
number of genome copies) for influenza A has been estimated by various authors.17-19 
Assuming that the 1 TCID50 is equal to 400 genome copies/mL, then an infectious aerosol 
dose (calculated to be 0.6 to 3 TCID50)20 would be 240–1200 copies/mL and an infectious 
intranasal dose (100-1000 TCID50)21-23 would be 40,000-400,000 copies/ml. The difference 
in the infectious dose between aerosol and direct nasal inoculation is at least 2 logs. It is 
likely that the infectious dose for aerosol transmission is also significantly less than that 
needed for indirect contact transmission. The copy number range for environmental swabs 
was 100 – 43000, with a median of 1200 copies/ml. We argue that while 38% of subjects 
contaminate their surroundings, the amount of virus recovered from the vast majority of 
environmental swabs does not represent an infectious dose. 
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Our data show similarities to findings from a randomized trial that investigated hand hygiene 
and surface contamination in Thailand.24,25 However, our results contrast with those of a 
study that detected influenza virus on over 50% of all swabs taken from a number of 
surfaces in the home and in child care centers.26 Differences between studies may be 
influenced by the strain of influenza virus; the subjects involved; swabbing and detection 
methods, including the timing of swabbing and the surfaces selected; environmental 
conditions; and the proportions of subjects taking antiviral drugs. Indeed we have 
demonstrated some of these points in the current study. Both swabbing and laboratory 
processing were more selective in Year 2, as we attempted to target surface samples that 
had a greater chance of positivity; the swab positive rates (1.4 vs. 10.7%) reflect this. For 
example, 4 out of 9 chosen surfaces in Year 1 (bedside table, dining table, patient table and 
windowsill) were not items that could be picked up or grasped by the hand, and in many 
instances, they were made of wood, a material that does not support virus survival27 (see 
supplementary data.) 
 
Two randomized clinical trials (RCTs) supporting the indirect contact route of transmission 
have shown significant effects of hand hygiene on the incidence of laboratory confirmed 
influenza and absenteeism due to ILI in school children28,29. Other RCTs report negative 
findings,30-32 and a systematic review and meta-analysis found no significant effect of hand 
hygiene on the reduction of laboratory confirmed influenza infections.33 Notwithstanding any 
positive trial results (which may reflect a reduction in transmission that involves hand to 
hand or hand to face touching but not fomites), the indirect contact route transmission 
pathway seems to be implausible. How likely is it that an infectious dose of virus can persist 
while passing along a transmission chain? Researchers studying rhinovirus transmission 
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concluded that an infective dose of virus is unlikely to reach the end of a transmission 
chain.34 Based on our data, we question how frequently an infectious dose of influenza virus 
persists while passing from infected secretions, to touched surfaces (our data), to hands, 
and finally, to mucous membranes to initiate infection in a second person. We argue that 
this may be rarer than is often reflected in infection control guidance for influenza where 
hand hygiene is often centrally emphasized.   
 
If the amount of virus released is key to transmission, then individuals who release the most 
virus, so called ‘super-producers’ or ‘super-spreaders’, are likely to be better transmitters 
than others.35 The amount of virus released by individuals is governed by a number of 
factors, of which the viral load and symptoms are most important. The findings from our 
study support the concept that super-spreaders of influenza infection via the indirect contact 
route might exist. On illness Day 3, nasal viral loads were significantly higher in those with 
positive surface swabs compared to those with negative surface swabs, and a significant 
correlation between nasal and surface viral loads was found. Furthermore, the symptom 
scores were generally higher (significantly so for the URT scores) in those with positive 
surface swabs. These findings suggest that individuals who release the most virus into the 
environment are likely to be responsible for the most surface contamination and therefore 
for the majority of transmissions that occur via the indirect contact route. In practical terms, 
we suggest that the intuitive feeling that patients with high viral loads and strong symptoms 
have the characteristics that makes them the most likely individuals to contaminate surfaces 
is indeed correct. 
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Influenza virus has been detected (by PCR) in air samples taken from medical facilities9,36,37 
and from the directly exhaled breath and coughs of infected patients.38-40 Our study 
demonstrates that samples of air collected from around infected subjects contain influenza 
virus. All of the particle sizes collected contained virus that was detectable by PCR, notably 
including the <1 µm and 1-4 µm fraction sizes, which are respirable (they can reach the 
distal airways of the respiratory tract),5 and health attendants require respirators, not 
surgical masks, to avoid exposure. Different sampling times did not always run concurrently, 
which may explain why longer sampling times did not always result in more virus being 
collected, as specific ‘shedding events’ would not have been captured equally. 
 
Attempts can be made to understand whether the PCR copy number found in the air 
samples could represent an infectious dose. Again assuming that 1 TCID50 is equal to 400 
genome copies/mL, then an infectious aerosol dose (calculated to be 0.6 to 3 TCID50)30 
would be 240–1200 copies/mL. Our samplers, operating at 3.5 L/min, commonly collected 
these amounts. By way of comparison, an adult human typically inhales 6 L/min. If the virus 
collected is infectious, then the majority of positive samples collected during this study could 
contain infectious doses of influenza. Although we were unable to culture virus from any air 
samples, the detection of live virus in air samples is known to be methodologically 
challenging; the difficulties include virus fragility, especially its susceptibility to desiccation, 
and the fact that the concentration of virus being sampled in the air is low. Thus, failure to 
identify live virus in air samples does not necessarily exclude its presence. 
 
There are a number of limitations to this study. First, the difficulty in recruiting subjects 
early in the course of their illness meant that the data on the initial days of illness were not 
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collected. The first few days of illness are usually times of peak symptoms and viral 
shedding (and by inference, environmental deposition). Due to logistic constraints, most 
analyses could only be attempted on illness days 3 and 4. Second, the comparison of 
symptom data between adults and children is imperfect. The data collection method was the 
same, and while this some allows for a comparison, it is clear that its interpretation must be 
guarded, as responses to the symptom diary card in children and adults may be different. A 
specific problem arises when parents estimate symptoms on the behalf of younger children. 
Third, the majority of subjects from around whom air samples were obtained (including all of 
those with positive samples) were selected on the basis of a positive rapid antigen test. This 
may have biased the air sampled group somewhat and led to a high proportion of positive 
air samples, as a positive rapid antigen test has been associated with higher nasal viral 
loads.41 Finally, no measurements or estimates of room air flow patterns or ventilation were 
made when collecting samples. Such parameters are likely to have an influence on the 
ability to detect virus in the air. 
 
Detecting virus, particularly live virus in the environment, is challenging; accessing the 
subject early in the course of illness, executing optimal sampling while preserving virus 
viability, and performing sensitive detection tests in the laboratory are all key factors and 
present logistical challenges. While based on limited data, these findings are of sufficient 
importance to justify further efforts to reproduce them, including further attempts to detect 
live virus, as they have potentially important implications for infection control strategies. 
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Figure Legends and Tables 
 
Figure 1: Participant flow diagram. 
 
 
Note: ‘Others’ consisted of influenza-like illness with no confirmed viral etiology or confirmed 
infections with rhinovirus or respiratory syncytial virus (RSV). Two influenza A(H1N1)pdm09 
cases were excluded on the basis of being recruited >5 days after symptom onset. 
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Table 1: Demographic characteristics of the participants, treatments, and outcomes. 
 
 
 
Setting: 
AC CC AH CH 
Total 
n (%) 
Enrolled 13 11 14 4 42 
Female sex 8 3 9 4 24 (57%) 
Median age (yrs) 
Range 
29 
21-58 
4 
2-12 
28 
19-57 
2.5 
0-15 
22 
0 - 58 
Ethnic group 
- White 
- Black 
- Asian 
 
10 
1 
2 
 
8 
0 
1 
 
8 
1 
5 
 
4 
0 
0 
 
30 (71%) 
2 (5%) 
8 (19%) 
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- Other 0 2 0 0 2 (5%) 
Mean time from 
symptom start to 
enrolment (days) 
 
2.2 
 
 
1.5 
 
 
2.4 
 
 
2.8 
 
 
2.1 
(Range 0-4) 
Mean duration of 
follow up (days) 
5.6 8.3 5.9 7.5 
 
6.6 
(Range 1-12) 
Rapid antigen test 
positive  
3/13 
(23%) 
7/9 
(78%) 
5/14 
(36%) 
1/4 
(25%) 
16 
(40%) 
Antiviral Treatment 
Any / 
Within 48 hours 
 
0/0 
 
4/3 13/8 3/1 
 
20/12 
(48/29%) 
High Dependency 
Care / Died during 
follow up 
0/0 0/0 1/0 1/0 2/0 
 
Note: AC = Adult Community, CC = Child Community, AH – Adult Hospital, CH = Child 
Hospital 
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Figure 2: The mean symptom scores of A(H1N1)pdm09 cases over time. 
 
Footnote: Data only shown where ≥3 observations were available 
 
 
 
Figure 3A+B: The percentage of subjects who shed virus against time.  
3A: Shedding by PCR 
3B: Shedding by culture 
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Table 2: Positive air sample results by location, age, particle size, and virus copies/mL. 
 Adult Adult Child Child Adult 
Subject 
setting 
(+ infected 
others) 
Hospital bed in 
side room 
Hospital bed in side 
room 
Playing in living room 
(6-year-old infected child 
also present) 
Cot on neonatal 
unit 
(2 infected 
neonates also 
present on ward) 
Bedroom 
Illness Day of 
sampling 
4 3 3 5 4 
Nasal Viral 
Load 
(copies/ml) 
173,000 8,250,000 24,520,000 18,480,000 4000 
Any surface 
swabs 
positive 
No 
Yes 
(Day 4) 
No No 
Yes 
(Day 3) 
27 
 
Room 
Temperature 
(0C) 
21.6 23.3 18.0 24.0 17.0 
Room 
Humidity 
(relative %) 
50 50 60 40 44 
Duration of 
sampling 
(hours) 
 
1 
 
3 
 
1 
 
2 
 
1 
 
3 
 
3 
 
3 
Approximate 
distance from 
subject (m) 
 
1-2 
 
≥2 
 
1-2 
 
≥2 
 
1-2 
 
≥2 
 
≥2 
 
1-2 
 
≥2 
 
1-2 
 
≥2 
 
1-2 
 
≥2 
 
≥2 
Particle size 
detected in 
(µm)  
<1 
1068 
 
 
 
<1 
238 
1-4 
 
 
 
 
 
1-4 
  <1 
13199 
1-4 
<1 
5156 
1-4 
 
 
1-4 
<1 
2149 
1-4 
<1 
2577 
1-4 
<1 
1287 
1-4 
 
 
1-4 
28 
 
 PCR 
copies/ml 
258 
>4 
511 
603 5179 
>4 
8210 
7107 
>4 
4028 
24231 
>4 
5603 
5166 
>4 
4889 
3527 
>4 
3639 
3889 
>4 
2245 
5388 
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Table 3: Viral loads and symptom scores compared between those with positive and those 
with negative surface swabs. 
 
Illness 
day 
GM nasal VL 
surface 
positive 
(95% CI) 
GM nasal VL 
surface 
negative 
(95% CI) 
GM ratio P value 
Day 3 
 
464225.5 
(79759.9, 
2701927.0) 
 
 
18072.4 
(1573.2, 
207613.6) 
 
25.7 
(1.75, 
376.0) 
0.021 
Day 4 
77514.8 
(7301.8, 
822885.5) 
118788.1 
(19080.1, 
739547.4) 
0.7 
(0.0, 10.5) 
 
0.753 
Illness 
day 
Mean URT 
score surface 
positive 
Mean URT 
score 
surface 
negative 
Mean 
difference 
P value 
Day 3 8.5 3.9 -4.6 0.002 
Day 4 6.6 3.6 -3.0 0.009 
Illness 
day 
Mean LRT 
score surface 
Mean LRT 
score 
Mean 
difference 
P value 
30 
 
positive surface 
negative 
Day 3 4.2 3.2 -1.0 0.140 
Day 4 3.8 2.7 -1.1 0.051 
 
Note: GM = Geometric Mean, VL = Viral Load, URT = Upper Respiratory Tract, LRT = Lower 
Respiratory Tract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
